SRXH
SRx Health Solutions Inc. AMEX Listed Jun 16, 2010$1.92
+4.92%
vs $1.83
Mkt Cap $18.9M
52w Low $0.96
2.3% of range
52w High $42.60
50d MA $4.00
200d MA $9.58
P/E (TTM)
—
EV/EBITDA
—
P/B
99.5x
Debt/Equity
15.3x
ROE
-1494.2%
P/FCF
-3.7x
RSI (14)
67.00
ATR (14)
$0.18
Beta
0.82
50d MA
$4.00
200d MA
$9.58
Avg Volume
7.5M
SRx Health Solutions Inc. is an integrated Canadian healthcare services provider operating within the specialty healthcare industry. The company offers comprehensive, integrated, and customized specialty healthcare services across all ten Canadian provinces. SRx combines industry knowledge, technology, and a patient-centric focus to create strategies and solutions aimed at improving the wellness of Canadians.
65 Queen St W · Tampa, FL 33034 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | — | -0.36 | — | 1.83 | -6.6% | +4.9% | — | — | — | — | — |
| May 14, 2026 | AMC | -0.26 | -1.20 | -361.5% | 8.28 | +1.4% | -9.4% | -0.3% | -7.8% | +2.2% | +9.8% | — |
| Feb 13, 2026 | AMC | — | -0.17 | — | 0.15 | -20.3% | -9.7% | +0.3% | -5.1% | -1.2% | -6.1% | — |
| Nov 10, 2025 | AMC | — | -24.00 | — | 0.21 | -3.0% | +5.0% | +9.3% | +0.8% | +0.5% | +0.8% | — |
| Sep 30, 2025 | AMC | -4.84 | -0.74 | +84.7% | 0.32 | -5.4% | +0.9% | +10.1% | -0.9% | +5.1% | -9.7% | — |
| May 15, 2025 | AMC | -2.21 | -0.37 | +83.3% | 0.57 | -11.4% | -16.7% | +21.7% | +15.6% | -6.0% | +1.4% | — |
| Mar 27, 2025 | AMC | -2.20 | -30.00 | -1264.6% | — | — | — | — | — | — | — | — |
| Nov 14, 2024 | AMC | -4.84 | -0.50 | +89.7% | — | — | — | — | — | — | — | — |
| Nov 12, 2024 | AMC | -2.20 | -0.73 | +66.8% | — | — | — | — | — | — | — | — |
| Aug 13, 2024 | AMC | -2.20 | -2.98 | -35.5% | — | — | — | — | — | — | — | — |
| Jun 30, 2024 | AMC | -2.20 | -0.10 | +95.3% | — | — | — | — | — | — | — | — |
| May 17, 2024 | AMC | -269.74 | -3.60 | +98.7% | — | — | — | — | — | — | — | — |
| Apr 12, 2024 | AMC | -4.40 | -20.84 | -373.6% | — | — | — | — | — | — | — | — |
| Mar 30, 2024 | AMC | — | -1.96 | — | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -1.58 | -1.32 | +16.7% | — | — | — | — | — | — | — | — |
No analyst ratings available.
No insider trades available.
8-K · 3.02
!! High
SRx Health Solutions Inc. -- 8-K 3.02: Unregistered Securities Offering
Jul 28
8-K · 1.01
!! High
SRx Health Solutions Inc. -- 8-K 1.01: Material Agreement
Jul 21
8-K · 3.02
!! High
CERO THERAPEUTICS HOLDINGS, INC. -- 8-K 3.02: Unregistered Securities Offering
Jul 17
8-K
SRx Health Solutions Inc. -- 8-K Filing
Jul 16
8-K · 7.01
! Medium
SRx Health Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
SRx Health Solutions held a virtual fireside chat with executives Kent Cunningham and Eric Jackson to discuss company strategy and operations, providing investors transparency on management's outlook.
Jul 15
8-K · 7.01
! Medium
SRx Health Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 10
8-K · 1.01
!! High
CERO THERAPEUTICS HOLDINGS, INC. -- 8-K 1.01: Material Agreement
Jun 26
8-K · 7.01
! Medium
SRx Health Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 26
8-K
SRx Health Solutions Inc. -- 8-K Filing
SRx Health Solutions will execute a reverse stock split effective July 6, 2026, consolidating shares to potentially improve its stock price and maintain exchange listing compliance.
Jun 24
8-K · 7.01
! Medium
SRx Health Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 18
8-K · 3.02
!! High
CERO THERAPEUTICS HOLDINGS, INC. -- 8-K 3.02: Unregistered Securities Offering
May 29
8-K · 5.02
!!! Very High
Onconetix, Inc. -- 8-K 5.02: Executive Change
Onconetix named Sammy Dorf as Chairman while removing Andrew Oakley and Thomas Meier from that role, also adding Josh Epstein as director in a leadership restructuring.
Apr 24
8-K · 7.01
! Medium
SRX Health Solutions, Inc. -- 8-K 7.01: Regulation FD Disclosure
SRX Health Solutions made a significant investment exceeding 10% of its treasury assets, potentially signaling strategic repositioning or capital deployment that could impact shareholder returns and financial flexibility.
Apr 22
8-K · 7.01
! Medium
SRX Health Solutions, Inc. -- 8-K 7.01: Regulation FD Disclosure
SRX Health Solutions disclosed material information via press release filing, which investors should review in the attached exhibit for details on company developments and potential impacts on the stock.
Apr 17
S-4
!!! Very High
Unknown — Merger Registration
SRXH shareholders face dilution and governance changes as the merger registration indicates a business combination will create a new ownership structure with potentially different management control and voting rights.
Apr 14
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
SRXH raised capital through unregistered preferred stock and warrant issuance, diluting existing shareholders while avoiding public market scrutiny, which typically signals financial distress or unfavorable valuation.
Mar 18
8-K · 1.01
! Medium
SRX Health Solutions, Inc. -- 8-K 1.01: Equity Issuance
SRX Health Solutions raised $30.46 million through a securities purchase agreement, providing capital for operations and growth initiatives.
Mar 3
8-K
SRX Health Solutions, Inc. -- 8-K Filing
SRX Health Solutions filed for Exchange listing approval of common shares issuable upon conversion of preferred shares, potentially diluting existing shareholders if the conversion occurs.
Feb 20
8-K · 7.01
! Medium
SRX Health Solutions, Inc. -- 8-K 7.01: Regulation FD Disclosure
SRX Health Solutions intends to redeem all outstanding Series A Convertible Preferred Stock shares, requiring preferred shareholders to either convert to common stock or receive redemption proceeds by the deadline.
Feb 12
Institutional (13F) — Top 5
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 68,000 | $16K | New | Dec 2025 |
| 2 | Ubs Group Ag | 85,742 | $11K | Added | Mar 2026 |
| 3 | Great Valley Advisor Group, Inc. | 14,825 | $3K | New | Dec 2025 |
| 4 | Rathbones Group Plc | 20,000 | $3K | New | Mar 2026 |
| 5 | Royal Bank Of Canada | 1,296 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 97,727 | $12K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 11,682 | $1K | May 2026 |
Valuation
Market Cap
$18.9M
Enterprise Value
$44.9M
P/E (TTM)
—
Forward P/E
1.04x
PEG Ratio
-0.00x
P/B
99.48x
P/S
—
P/FCF
-3.68x
EV/EBITDA
—
Shares Out
21.1M
Financials (TTM)
Revenue
-$38.5M
Net Income
-$40.4M
EBITDA
-$8.1M
Free Cash Flow
-$11.0M
Op Cash Flow
-$8.1M
EPS Basic
$-2.13
EPS Diluted
$-79.04
EPS Forward
$1.84
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$8.4M
Total Liab.
$8.0M
Total Equity
$407K
Cash
$1.8M
LT Debt
$6.2M
Book Value/Sh
$0.02
Debt/Equity
15.33x
Current Ratio
2.29
Quick Ratio
1.71
Returns & Growth
ROE
-1494.2%
ROA
-194.6%
ROIC
-168.9%
Rev Growth YoY
-81.3%
EPS Growth YoY
-2030.0%
Price Returns
2W
+39.1%
1M
-16.9%
3M
-74.4%
6M
-78.5%
12M
-93.6%
Technicals
52W High
$42.60
52W Low
$0.96
50d MA
$4.00
200d MA
$9.58
RSI (14)
67.00
ATR (14)
$0.18
Beta
0.82
Avg Volume
7.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 2:53am
· Source: financialmodelingprep.com